Universität zu Köln

Petricevic, Branka, Kabiljo, Julijan ORCID: 0000-0002-6778-6648, Zirnbauer, Rebecca ORCID: 0000-0002-3921-4001, Walczak, Henning, Laengle, Johannes ORCID: 0000-0003-4771-1398 and Bergmann, Michael (2022). Neoadjuvant immunotherapy in gastrointestinal cancers - The new standard of care? Semin. Cancer Biol., 86. S. 834 - 851. LONDON: ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD. ISSN 1096-3650

Full text not available from this repository.

Abstract

The development of immune checkpoint inhibitors (ICI) offers novel treatment possibilities for solid cancers, with the crucial benefit of providing higher cure rates. These agents have become part of standard treatments in the metastatic and adjuvant setting for select cancers, such as melanoma, non-small cell lung cancer (NSCLC) or urological malignancies. Currently, there is ample clinical interest in employing ICI in a neoadjuvant setting with a curative intent. This approach is especially supported by the scientific rationale that ICI primarily stimulate the host immune system to eradicate tumor cells, rather than being inherently cytotoxic. Aside from tumor downstaging, neoadjuvant immunotherapy offers the potential of an in situ cancer vaccination, leading to a systemic adjuvant immunological effect after tumor resection. Moreover, preclinical data clearly demonstrate a synergistic effect of ICI with radiotherapy (RT), chemoradiotherapy (CRT) or chemotherapy (ChT). This review harmonizes preclinical concepts with real world data (RWD) in the field of neoadjuvant ICI in gastrointestinal (GI) cancers and discusses their limitations. We believe this is a crucial approach, since up to now, neoadjuvant strategies have been primarily developed by clinicians, whereas the advances in immunotherapy primarily originate from preclinical research. Currently there is limited published data on neoadjuvant ICI in GI cancers, even though neoadjuvant treatments including RT, CRT or ChT are frequently employed in locally advanced/ oligometastatic GI cancers (i.e. rectal, pancreatic, esophagus, stomach, etc.). Utilizing established therapies in combination with ICI provides an abundance of opportunities for innovative treatment regimens to further improve survival rates.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Petricevic, Branka UNSPECIFIED UNSPECIFIED UNSPECIFIED Kabiljo, Julijan UNSPECIFIED orcid.org/0000-0002-6778-6648 UNSPECIFIED Zirnbauer, Rebecca UNSPECIFIED orcid.org/0000-0002-3921-4001 UNSPECIFIED Walczak, Henning UNSPECIFIED UNSPECIFIED UNSPECIFIED Laengle, Johannes UNSPECIFIED orcid.org/0000-0003-4771-1398 UNSPECIFIED Bergmann, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-675218
DOI:	10.1016/j.semcancer.2022.05.015
Journal or Publication Title:	Semin. Cancer Biol.
Volume:	86
Page Range:	S. 834 - 851
Date:	2022
Publisher:	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
Place of Publication:	LONDON
ISSN:	1096-3650
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language REGULATORY T-CELLS; CLINICAL-PRACTICE GUIDELINES; INFLUENZA-A VIRUS; ACQUIRED-RESISTANCE; ANTITUMOR IMMUNITY; POOLED ANALYSIS; PD-1 BLOCKADE; COLON-CANCER; OPEN-LABEL; NIVOLUMAB Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/67521